IRIS
ATZENI, Fabiola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.811
AS - Asia 4.504
EU - Europa 3.107
SA - Sud America 2.221
AF - Africa 141
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 8
Totale 16.802
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.685
SG - Singapore 2.016
BR - Brasile 1.963
IE - Irlanda 1.237
CN - Cina 1.078
HK - Hong Kong 649
SE - Svezia 638
IT - Italia 359
RU - Federazione Russa 258
VN - Vietnam 234
DE - Germania 145
AR - Argentina 101
PL - Polonia 100
IN - India 92
GB - Regno Unito 85
IQ - Iraq 57
FR - Francia 51
BD - Bangladesh 49
TR - Turchia 48
ZA - Sudafrica 48
CA - Canada 46
MX - Messico 46
FI - Finlandia 45
NL - Olanda 45
EC - Ecuador 35
UZ - Uzbekistan 33
AT - Austria 30
PK - Pakistan 29
ID - Indonesia 25
UA - Ucraina 25
VE - Venezuela 24
CO - Colombia 20
PY - Paraguay 20
BE - Belgio 19
JP - Giappone 19
BO - Bolivia 17
EG - Egitto 17
PE - Perù 17
KE - Kenya 16
CL - Cile 15
IL - Israele 15
JO - Giordania 15
KZ - Kazakistan 15
MA - Marocco 15
AE - Emirati Arabi Uniti 14
AZ - Azerbaigian 14
IR - Iran 14
ES - Italia 13
DZ - Algeria 11
KG - Kirghizistan 10
LB - Libano 10
NP - Nepal 10
TN - Tunisia 10
PA - Panama 9
OM - Oman 8
UY - Uruguay 8
CI - Costa d'Avorio 7
DO - Repubblica Dominicana 7
AM - Armenia 6
BY - Bielorussia 6
EU - Europa 6
PT - Portogallo 6
AL - Albania 5
AO - Angola 5
CH - Svizzera 5
CZ - Repubblica Ceca 5
SA - Arabia Saudita 5
SN - Senegal 5
AU - Australia 4
BH - Bahrain 4
DK - Danimarca 4
GE - Georgia 4
JM - Giamaica 4
NI - Nicaragua 4
PS - Palestinian Territory 4
QA - Qatar 4
RO - Romania 4
SY - Repubblica araba siriana 4
CR - Costa Rica 3
GA - Gabon 3
GR - Grecia 3
TW - Taiwan 3
BG - Bulgaria 2
BN - Brunei Darussalam 2
CY - Cipro 2
EE - Estonia 2
GT - Guatemala 2
HN - Honduras 2
HU - Ungheria 2
KR - Corea 2
LA - Repubblica Popolare Democratica del Laos 2
LT - Lituania 2
MN - Mongolia 2
MY - Malesia 2
NZ - Nuova Zelanda 2
RS - Serbia 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
Totale 16.783
Salva come PNG Salva come JPEG
Città #
Dublin 1.235
Chandler 1.009
Singapore 975
Dallas 912
Hong Kong 643
Ashburn 618
Beijing 545
Nyköping 456
New York 330
Princeton 270
Jacksonville 249
Dearborn 245
Medford 229
Des Moines 198
Cambridge 166
São Paulo 165
Moscow 160
Los Angeles 149
Redondo Beach 117
Buffalo 101
The Dalles 98
Warsaw 96
Messina 93
Ho Chi Minh City 81
Rio de Janeiro 81
Ann Arbor 74
Munich 74
Wilmington 59
Belo Horizonte 58
Pune 57
Hanoi 45
Nanjing 42
Shenyang 40
Tianjin 38
Jinan 33
Tashkent 31
Seattle 28
Porto Alegre 27
Brasília 26
Milan 23
Boardman 22
Nuremberg 22
Baghdad 21
Buenos Aires 21
Falls Church 21
Santa Clara 21
Turku 21
Campinas 20
Council Bluffs 20
Guangzhou 20
Johannesburg 20
Brooklyn 19
Brussels 19
Rome 19
San Mateo 19
Tokyo 19
Catania 18
Frankfurt am Main 18
Haikou 18
Hebei 18
London 18
Ningbo 18
Salvador 18
Amsterdam 17
Curitiba 17
Montreal 17
Zhengzhou 17
Caxias do Sul 16
Fortaleza 16
Guarulhos 16
San Francisco 16
Vienna 16
Cape Town 15
Norwalk 15
Dhaka 14
Dong Ket 14
Hangzhou 14
Nairobi 14
Phoenix 14
Amman 13
Aracaju 13
Baku 13
Belém 13
Mexico City 13
Nanchang 13
Quito 13
Recife 13
Ribeirão Preto 13
Santo André 13
Uberlândia 13
Atlanta 12
Istanbul 12
Lappeenranta 12
Orem 12
São Gonçalo 12
Asunción 11
Changsha 11
La Paz 11
Maceió 11
Maringá 11
Totale 10.832
Salva come PNG Salva come JPEG
Nome #
CORRELATION BETWEEN DISEASE ACTIVITY AND CARDIOVASCULAR PARAMETERS IN PATIENTS WITH ANKYLOSING SPONDYLITIS 134
Algo-dysfunctional syndromes: a critical digest of the recent literature 127
Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors 126
CARDIOVASCULAR EVALUATION USING NON-INVASIVE IMAGING METHODS IN PATIENTS WITH ANKYLOSING SPONDYLITIS BEFORE AND AFTER 12 MONTHS OF TREATMENT WITH ANTI-TNF DRUGS 115
A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis 110
The microbiome in connective tissue diseases and vasculitides: An updated narrative review 107
Certainties and uncertainties concerning the contribution of pericytes to the pathogenesis of systemic sclerosis 107
Anti-tumour necrosis factor-α antibodies and B cell homeostasis in human inflammatory bowel diseases 107
BODY MASS INDEX, SMOKING STATUS AND RESPONSE TO RITUXIMAB IN RHEUMATOID ARTHRITIS: A REAL-LIFE STUDY. 105
Central nervous system involvement in rheumatoid arthritis patients and the potential implications of using biological agents 104
Biomarkers in Rheumatoid Arthritis 103
Assessment of enthesis in patients with psoriatic arthritis and fibromyalgia using clinical examination and ultrasound 99
Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: A case series 96
Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study 96
Cancer risk and tumour necrosis factor inhibitors in patients with inflammatory arthritis 95
CLINICAL AND ULTRASONOGRAPHIC EVALUATION IN A COHORT OF SUSTAINED REMISSION RHEUMATOID ARTHRITIS PATIENTS AFTER STOPPING BIOLOGIC THERAPY: A SINGLE CENTER EXPERIENCE , 94
Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: A one-year prospective study 93
A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data 93
Anti-adalimumab and anti-certolizumab antibodies titers after discontinuation of adalimumab: Two case reports 93
Cross Cultural Adaptation and Validation of Italian Version of the Leeds Assessment of Neuropathic Symptoms and Signs Scale and Pain DETECT Questionnaire for the Distinction between Nociceptive and Neuropathic Pain 90
Are the ACR 2010 diagnostic criteria for fibromyalgia better than the 1990 criteria? 90
B Lymphocyte intestinal homing in inflammatory bowel disease 88
A Review of Chronic Musculoskeletal Pain: Central and Peripheral Effects of Diclofenac 88
The neuropathic pain features in Psoriatic Arthritis: a cross-sectional evaluation of prevalence and associated factors 88
Recurrent intracranial hemorrhage and cerebral venous sinus thrombosis: an atypical case of Neuro-Behçet’s Syndrome 88
Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab 88
Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients 85
An update on emerging drugs for fibromyalgia treatment 85
A possible link between ankylosing spondylitis and periodontitis: A systematic review and meta-analysis 84
A proteinuria cut-off level of 0.7 g /day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: Data from the MAINTAIN Nephritis Trial 83
From autoinflammation to autoimmunity: old and recent findings 83
Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry 82
Biological agents in rheumatoid arthritis: A cross-link between immune tolerance and immune surveillance 82
Immunogenicity and autoimmunity during anti-TNF therapy 81
Subclinical atherosclerosis and history of cardiovascular events in Italian patients with rheumatoid arthritis 81
Anti-citrullinated peptide antibodies and rheumatoid factor isotypes in the diagnosis of rheumatoid arthritis: An assessment of combined tests 81
A Proposed Serum Calprotectin IgG Cut-Off Level for Diagnosing Inflammatory Arthritis 80
Ultrasonographyc Evaluation of Metacarpophalangeal Joints Can be Useful in the Differential Diagnosis of Early Rheumatoid Arthritis and Early Spondyloarthritis. A Monocentric Preliminary Study 79
Hyperbaric oxygen treatment of fibromyalgia: a prospective observational clinical trial 79
Safety of Abatacept in Rheumatoid Arthritis with Serologic Evidence of Past or Present Hepatitis B Virus Infection 78
One year in review 2019: fibromyalgia 77
Efficacy and Safety of Biosimilar and Originator Etanercept in Rheumatoid Arthritis Patients: Real-Life Data 76
Retrotransposons shuttling genetic and epigenetic information from the nuclear to the mitochondrial compartment: Do they play a pathogenetic role in scleroderma? 75
An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis 74
Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents 74
Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry 74
PLA1/A2 polymorphism of the platelet glycoprotein receptors IIIA in Behçet's disease 73
Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study 73
Differential Diagnosis of Vasovagal Syncope: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. 73
EULAR recommendations for management of fibromyalgia 73
Measurement of Serum Klotho in Systemic Sclerosis 72
Cardiovascular Imaging Techniques in Systemic Rheumatic Diseases 72
Co-Occurrence and Characteristics of Patients With Axial Spondyloarthritis Who Meet Criteria for Fibromyalgia: Results From a UK National Register 72
Systemic rheumatic diseases: from biological agents to small molecules 72
Noninvasive imaging methods for evaluating cardiovascular involvement in patients with rheumatoid arthritis before and after anti-TNF drug treatment 72
EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update 71
Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis Trial 71
Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: Real-life data from the LORHEN registry 71
Cardiovascular risk in ankylosing spondylitis and the effect of anti-TNF drugs: a narrative review 71
Longterm retention of tumor necrosis factor-α inhibitor therapy in a large Italian cohort of patients with rheumatoid arthritis from the GISEA Registry: An appraisal of predictors 70
What are the dangers of biological therapy discontinuation or dose reduction strategies when treating rheumatoid arthritis? 70
Chronic widespread pain in the spectrum of rheumatological diseases 70
Psoriatic arthritis: From pathogenesis to pharmacologic management 70
MEASUREMENT OF SERUM ALPHA-KLOTHO IN SYSTEMIC SCLEROSIS PATIENTS: RESULTS FROM A PIVOTAL STUDY. 70
TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same? 70
Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register 70
CC chemokine receptor 5 polymorphism in Italian patients with Beḩet's disease 69
Measuring psoriatic disease in clinical practice. An expert opinion position paper 69
Rheumatic diseases and autoimmune vascular dementia 68
EULAR revised recommendations for the management of fibromyalgia 68
Prescribing motivations and patients’ characteristics related to the use of biologic drugs in adult-onset Still’s disease: analysis of a multicentre “real-life” cohort 68
RELATIONSHIP BETWEEN ULTRASONOGRAPHIC SALIVARY GLANDS ABNORMALITIES AND SUBCLINICAL CARDIOVASCULAR INVOLVEMENT IN PATIENTS WITH PRIMARY SJÖGREN SYNDROME 68
DOSE REDUCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS RESPONDING TO THE STANDARD RITUXIMAB REGIMEN. 68
Paradoxical Expansion of Th1 and Th17 Lymphocytes in Rheumatoid Arthritis Following Infliximab Treatment: a Possible Explanation for a Lack of Clinical Response 67
SDAI AS PREDICTOR OF 1-YEAR EFFICACY OF THE FIRST TNF BLOCKER IN CLINICAL PRACTICE. 67
Toll-like receptor 4 (TLR4) gene polymorphisms in Italian patients with Behçet's disease 66
AxSpA patients who also meet criteria for fibromyalgia: identifying distinct patient clusters using data from a UK national register (BSRBR-AS) 66
Do DMARDs and biologic agents protect from cardiovascular disease in patients with inflammatory arthropathies? 66
How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project) 66
Patients Failing to Fulfill 2016 Criteria for Fibromyalgia Represent a Truly Different Population Subset 66
Infections and Biological Therapy in Patients with Rheumatic Diseases 65
The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: Results of an italian multicentre study 65
Pain in systemic sclerosis 65
Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients 65
PREVALENCE OF CHRONIC WIDESPREAD PAIN IN SSC PATIENTS: PRELIMINARY DATA 64
The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts 64
Impaired lung transfer factor in fibromyalgia syndrome 64
Clinical comparison of QUANTA flash dsDNA chemiluminescent immunoassay with four current assays for the detection of anti-dsDNA autoantibodies 63
Long-term safety of abatacept in patients with rheumatoid arthritis 63
Efficacy of Cannabis Flos in Patients with Fibromyalgia: A Monocentric 63
Predicting response to anti-TNF treatment in rheumatoid arthritis patients 63
Autoantibody profile during short-term infliximab treatment for Crohn's disease: A prospective cohort study 62
Autoimmune hepatitis and allergic reactions during anti-TNFα treatment 62
Reactivation of occult hepatitis B virus infection under treatment with abatacept: A case report 62
Anti-thyroid antibodies and thyroid dysfunction in rheumatoid arthritis: Prevalence and clinical value 62
The effect of tumor necrosis factor-α antagonists on arterial stiffness in rheumatoid arthritis: a literature review 62
Web/Internet-based telemonitoring of a randomized controlled trial evaluating the time-integrated effects of a 24-week multicomponent intervention on key health outcomes in patients with fibromyalgia 62
Serum klotho concentrations inversely correlate with the severity of nailfold capillaroscopic patterns in patients with systemic sclerosis 62
Novel pharmaceutical options for treating fibromyalgia 62
Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction. 62
Totale 7.847
Salva come PNG Salva come JPEG
Categoria #
all - tutte 85.172
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 85.172
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021331 0 0 0 0 0 13 51 97 59 47 47 17
2021/20221.179 9 60 3 30 96 21 27 51 36 55 169 622
2022/20233.443 311 221 155 315 169 347 19 199 1.556 14 110 27
2023/20241.117 94 133 190 83 69 385 7 33 4 32 7 80
2024/20254.830 74 44 93 295 149 153 147 1.061 1.342 336 399 737
2025/20264.666 489 956 1.159 762 1.134 166 0 0 0 0 0 0
Totale 17.440